Be The First To
Call it The Silence of the Genes. Alnylam Pharmaceuticals runs interference with RNA to prevent disease. RNA interference (RNAi) technology developed by the biotech firm can selectively shut off harmful genes. The company is developing a pipeline of candidates both individually and through collaborations with other drugmakers. Its disease targets include rare genetic disorder ATTR (transthyretin-mediated amyloidosis) and RSV (respiratory syncytial virus), a common childhood viral infection. Additional R&D programs target neurological disorders, cardiovascular conditions...
This is the employer's chance to tell you why you should work for them. The information provided is from their perspective.
|Salaries in USD||Avg. Salary|| |
10 Alnylam Salaries
8 Alnylam Salaries
3 Alnylam Salaries
= Salary Range
= Anonymous Salary Range
Accepted Offer – Reviewed Jul 25, 2013
Interview Details – Hiring was fast and aggressive. I only had a weekend to review the offer and submit my answer. The interview did not require a presentation and met with colleagues on 2 different visits. Everyone was nice and the discussions focused on relevant information. – Full Interview
Nothing out of the ordinary – Answer Question